Study of GNC-038 for active rheumatoid arthritis
Treatments studied
Part of Bones, joints & muscles, Immune system & allergy, Skin clinical trials.
This trial tests a new experimental antibody called GNC-038 for people with moderate to severe rheumatoid arthritis (RA) that hasn't responded well enough to standard treatments. It aims to see if targeting specific immune cells can reduce inflammation and improve symptoms.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have been diagnosed with rheumatoid arthritis for more than 6 months and currently have moderate to severe active disease.
- You are between 18 and 75 years old and have a life expectancy of at least 6 months.
- You have been on a steady dose of your current RA medications for at least 30 days.
- You have stopped certain other RA drugs (like leflunomide, JAK inhibitors, or anti-TNF drugs) for the required time before joining.
- Your blood tests show signs of inflammation (high ESR or CRP) and you test positive for RA-related antibodies.
- You have CD19+ B cells (a type of immune cell) in your blood.
- You have not received certain prior treatments like B-cell therapies, CAR-T therapy, or other experimental drugs within specific timeframes.
- Your organ function is adequate, and you have no active infections like hepatitis or HIV.
- You are willing to use effective contraception if you could become pregnant or father a child, and follow the study schedule.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests an experimental drug for people with rheumatoid arthritis who have not had success with other treatments. It aims to see if the drug can help reduce joint pain and swelling.
This trial tests a new medicine called CIT-013 for people with rheumatoid arthritis. It aims to see if CIT-013 can help reduce joint swelling and pain when added to your current treatment.
This study tests a new medication called AZD1163 for people with rheumatoid arthritis (RA) that hasn't responded well enough to standard treatments. It aims to see if the drug can safely reduce joint swelling and pain.
This trial tests a new medication (BMS-986454) for people with rheumatoid arthritis who haven't responded well enough to methotrexate. It aims to see if the drug is safe and how it works in the body.
This study tests a new investigational drug called SR-878 for people with rheumatoid arthritis. It aims to see if the drug is safe and tolerable. You may join if you are between 18 and 60, have RA for at least 3 months, and take a stable dose of methotrexate.
This study tests an investigational medicine called PTC844 in people with active rheumatoid arthritis (RA) to see if it can reduce joint inflammation and symptoms. It may be an option if you've just been diagnosed or if your current treatment isn't working well.
Hear when a new Rheumatoid arthritis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.